A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Crumbl has built its viral desserts into a big business, with franchisees operating over 1,100 stores in the US, Puerto Rico ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

The Chinese company ran large clinical trials suggesting that in local patients, it appeared just as effective as Lilly’s bestselling Zepbound in helping patients lose weight. The treatment also ...

Eli Lilly (LLY) shares were up 0.2% in premarket trade, even as it is now facing its first major competitor in China. Suzhou-based Innovent Biologics gained regulatory approval last week for its ...

More than a dozen Houston medical professionals and health care business owners were charged as part of a nationwide ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

This week, there are new and surprising opportunities. The week begins on Sunday, December 22, when the moon in Libra trines Pluto in your own sign of Aquarius and your house of physical energy. Today ...